

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines Emerging Biomarkers for Primary Prevention of Cardiovascular Disease and Stroke

These include all reported relationships within the previous 2 years that may be relevant to the guidelines document.

		Grant	Other Research Support	Speakers Bureau	Honoraria	Expert Witnesses	Ownership Interest	Consultant Advisory Board	Institution Employer	Other Disclosures
Myers	Significant (>\$10K)/Other	None	None	None	None	None	None	None	None	None
Christenson	Significant (>\$10K)/Other	Not reported	Siemens Medical Diagnostics	Not reported	Not reported	Not reported	Not reported	Siemens Medical Diagnostics, Biosite Diagnostics, and Abbott Diagnostics	Not reported	Not reported
Cushman	Significant (>\$10K)/Other	None	GlaxoSmithKline	None	None	None	None	GlaxoSmithKline	None	None
Grundy	Significant (>\$10K)/Other	Pfizer	None	None	None	None	None	None	None	Merck, Merck/Schering-Plough, AstraZeneca, Pfizer, and GlaxoSmithKline
Ballantyne	Significant (>\$10K)/Other	None	Abbott, AstraZeneca, GlaxoSmithKline, Merck, Sanofi-Synthelabo,	AstraZeneca, GlaxoSmithKline, Merck, Merck/Schering-Plough, Pfizer,	Abbott, AstraZeneca, GlaxoSmithKline, Merck, Merck/Schering-Plough,	None	None	Abbott, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, KOWA,	None	None

